<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2023-3-1-61-67</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE COMPLICATIONS, QUALITY OF LIFE, AND FOLLOW-UP CARE OF ONCOHEMATOLOGICAL PATIENTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ ОСЛОЖНЕНИЯ, КАЧЕСТВО ЖИЗНИ И ДИСПАНСЕРНОЕ НАБЛЮДЕНИЕ ОНКОГЕМАТОЛОГИЧЕСКИХ БОЛЬНЫХ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Application of autonomous extended infusion therapy systems in treatment of patients with hemoblastoses. Experience of the Oncohematology Division of the Clinical Hospital “Lapino”</article-title><trans-title-group xml:lang="ru"><trans-title>Применение систем для независимой пролонгированной инфузионной терапии в лечении пациентов с гемобластозами. Опыт отделения онкогематологии Клинического госпиталя «Лапино»</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8443-8816</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryabukhina</surname><given-names>Yu. E.</given-names></name><name xml:lang="ru"><surname>Рябухина</surname><given-names>Ю. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>Юлия Евгеньевна Рябухина</p><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><email>gemonk.yur@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p><p>Bld. 2, 8 Trubetskaya St., Moscow 119991</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p><p>119991 Москва, ул. Трубецкая, 8, стр. 2</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2359-0547</contrib-id><name-alternatives><name xml:lang="en"><surname>Abbasbeyli</surname><given-names>F. M.</given-names></name><name xml:lang="ru"><surname>Аббасбейли</surname><given-names>Ф. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6229-7300</contrib-id><name-alternatives><name xml:lang="en"><surname>Timofeeva</surname><given-names>O. L.</given-names></name><name xml:lang="ru"><surname>Тимофеева</surname><given-names>О. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1469-2365</contrib-id><name-alternatives><name xml:lang="en"><surname>Valiev</surname><given-names>T. T.</given-names></name><name xml:lang="ru"><surname>Валиев</surname><given-names>Т. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 2, 8 Trubetskaya St., Moscow 119991</p></bio><bio xml:lang="ru"><p>119991 Москва, ул. Трубецкая, 8, стр. 2</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5353-8857</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhukov</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Жуков</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111;</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8509-0954</contrib-id><name-alternatives><name xml:lang="en"><surname>Kupryshina</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Купрышина</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-03-16" publication-format="electronic"><day>16</day><month>03</month><year>2023</year></pub-date><volume>3</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>61</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2023-03-15"><day>15</day><month>03</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-03-15"><day>15</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, АБВ-пресс</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/65">https://mdonco.abvpress.ru/jour/article/view/65</self-uri><abstract xml:lang="en"><p>Use of microinfusion elastomeric pumps for extended administration of antitumor drugs improves patients’ quality of life during prolonged cyclic treatment because of the absence of venous complications and infusion allergic reactions during administration of cytostatic agents and targeted drugs.</p></abstract><trans-abstract xml:lang="ru"><p>Применение микроинфузионных эластомерных помп для пролонгированного введения противоопухолевых лекарственных препаратов способствует улучшению качества жизни пациентов, получающих длительное цикловое лечение. Это во многом достигается за счет отсутствия венозных осложнений и инфузионных аллергических реакций при введении цитостатических агентов и таргетных препаратов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>microinfusion elastomeric pumps</kwd><kwd>quality of life</kwd><kwd>cytostatic agents</kwd><kwd>targeted drugs</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>микроинфузионные эластомерные помпы</kwd><kwd>качество жизни</kwd><kwd>цитостатические агенты</kwd><kwd>таргетные препараты</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kreidieh F.Y., Moukadem H.A., El Saghir N.S. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016;7(1):87–97. DOI: 10.5306/wjco.v7.i1.87</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Skryabina E.A., Dunn T.S. Disposable infusion pumps. Am J Health Syst Pharm 2006;63(13):1260–8. DOI: 10.2146/ajhp050408</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Evans J.M., Qiu M., MacKinnon M. et al. A multi-method review of home-based chemotherapy. Eur J Cancer Care (Engl) 2016;25(5):883–902. DOI: 10.1111/ecc.12408</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Giuliano K.K., Penoyer D., Mahuren R.S., Bennett M. Intravenous smart pumps during actual clinical use: a descriptive comparison of primary and secondary infusion practices. J Infus Nurs 2021;44(3):128–36. DOI: 10.1097/NAN.0000000000000415</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mann J.R., Abrams L.D., Deeble T.J., Stuart J. Prolonged intermittent cytotoxic therapy in children using a microinfusion pump. Lancet 1970;2(7683):1116–7. DOI: 10.1016/s0140-6736(70)92301-9</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Yu C.H., Jou S.T., Su Y.H. et al. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia. Cancer 2023;129(5):790–802. DOI: 10.1002/cncr.34606</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Robinson H.R., Qi J., Cook E.M. et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood 2018;132(5):521–32. DOI: 10.1182/blood-2018-02-830992</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Locatelli F., Zugmaier G., Rizzari C. et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. Jama 2021;325(9):843–54. DOI: 10.1001/jama.2021.0987</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Abdurakhmanov D.T., Abuzarova G.R., Ageeva T.A. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Ed. by I.V. Poddubnaya, V.G. Savchenko. Moscow, 2018. 470 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Абдурахманов Д.Т., Абузарова Г.Р., Агеева Т.А. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. проф. И.В. Поддубной, проф. В.Г. Савченко. М., 2018. 470 с.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Buidenok Yu.V. Recommendations for the prevention and treatment of the effects of extravasation of antitumor drugs. Prakticheskiye rekomendatsii RUSSCO = Malignant tumours: Practical recommendations of RUSSCO 2021;11(3s2):156–66. (In Russ.). DOI: 10.18027/2224-5057-2021-11-3s2-48</mixed-citation><mixed-citation xml:lang="ru">Буйденок Ю.В. Рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Практические рекомендации RUSSCO 2021;11(3s2):156–66. DOI: 10.18027/2224-5057-2021-11-3s2-48</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Babicheva L.G., Tumyan G.S., Osmanov E.A. et al. Follicular lymphoma. Sovremennaya oncologiya = Journal of Modern Oncology 2020;22(2):34–51. DOI: 10.26442/18151434.2020.2.200131</mixed-citation><mixed-citation xml:lang="ru">Бабичева Л.Г., Тумян Г.С., Османов Е.А. и др. Фолликулярная лимфома. Современная онкология 2020;22(2):34–51. DOI: 10.26442/18151434.2020.2.200131</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Dimopoulos M.A., Moreau P., Terpos E. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(3):309–22. DOI: 10.1016/j.annonc.2020.11.014</mixed-citation></ref></ref-list></back></article>
